Abstract
The antiviral activity of a series of nitrated uracil derivatives, including 5-nitrouracil, 1-methyl-5-nitrouracil, 1,3-dimethyl-5-nitrouracil, 5-nitro-2'-deoxyuridine (5-nitro-dU), 3'-O,5-dinitro-2'-deoxyuridine, 5-nitro-2'-deoxyuridine 5'-monophosphate (5-nitro-dUMP), and 3'-O,5-dinitro-2'-deoxyuridine 5'-monophosphate, was evaluated in primary rabbit kidney or human skin fibroblast cultures challenged with vaccinia, herpes simplex, or vesicular stomatitis virus. The most remarkable antiviral activity was shown by 5-nitro-dU and 5-nitro-dUMP, which inhibited the replication of vaccinia virus at concentrations as low as 0.1-0.4 µg/ml. Somewhat higher concentrations were required to inhibit the replication of herpes simplex virus (1-4 µg/ml for 5-nitro-dU and 40-100 µg/ml for 5-nitro-dUMP). Neither 5-nitro-dU nor its 5'-monophosphate was inhibitory to vesicular stomatitis virus at concentrations up to 100 µg/ml. Combination of 5-nitro-dU with 5-iodo-2'-deoxyuridine (5-iodo-dU) resulted in an increased antiviral activity over the activity of the compounds used individually, suggesting that 5-nitro-dU and 5-iodo-dU act at different steps in DNA biosynthesis. In fact, 5-nitro-dU and its 5'-monophosphate effectively blocked the incorporation of [14C]2'-deoxyuridine into host cell DNA, but neither compound inhibited the incorporation of [3H]2'-deoxythymidine, pointing to thymidylate synthetase as a specific target for the action of 5-nitro-dU (or 5-nitro-dUMP). Inhibition of thymidylate synthetase would account for the antiviral activity of 5-nitro-dU, since the inhibitory effect of 5-nitro-dU on vacciia virus replication could be readily reversed by 2'-deoxythymidine, but not by 2'-deoxyuridine or 2'-deoxycytidine. Other deoxythymidine analogues that were found to inhibit deoxyuridine incorporation, but not deoxythymidine incorporation, and could therefore be assumed to block thymidylate synthetase selectively in vivo, include 5-fluoro-, 5-trifluoromethyl-, 5-cyamo-, and 5-thiocyamato-2'-deoxyuridine.
- Copyright © 1978 by Academic Press, Inc.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|